Ranitidine ( DrugBank: Ranitidine )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	2
65	原発性免疫不全症候群	1

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03368664 (ClinicalTrials.gov)	October 24, 2017	2/11/2017	A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRM ...	A Multi-center, Open-label, Single-arm, Before and After Switch Study to Evaluate the Efficacy, Safe ...	Multiple Sclerosis	Drug: Alemtuzumab GZ402673;Drug: Glatiramer acetate;Drug: Beta-Interferon;Drug: Methylprednisolone;D ...	Genzyme, a Sanofi Company	NULL	Active, not recruiting	10 Years	17 Years	All	50	Phase 3	Austria;Belgium;France;Italy;Netherlands;Poland;Portugal;Russian Federation;Turkey;United Kingdom;Bu ...
2	NCT02205489 (ClinicalTrials.gov)	October 2014	29/7/2014	Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA	Single Arm Study To Assess Comprehensive Infusion Guidance For The Management Of The Infusion- Assoc ...	Relapsing-remitting Multiple Sclerosis	Drug: Alemtuzumab GZ402673;Drug: cetirizine;Drug: ranitidine;Drug: methylprednisolone;Drug: aciclovi ...	Genzyme, a Sanofi Company	NULL	Completed	18 Years	N/A	Both	58	Phase 4	Belgium;France;Netherlands;Spain

臨床試験数 : 482 / 薬物数 : 653 - (DrugBank : 119) / 標的遺伝子数 : 92 - 標的パスウェイ数 : 212

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00527878 (ClinicalTrials.gov)	September 2007	8/9/2007	Effect of Ranitidine on Hyper-IgE Recurrent Infection (Job's) Syndrome	A Double-Blind, Randomized, Placebo-Controlled Cross-Over Study Assessing the Role of Pathogen-Speci ...	JOB's Syndrome;Hyper-IgE Recurrent Infection Syndrome;Immune Deficiency	Drug: Ranitidine;Drug: Placebo	National Institute of Allergy and Infectious Diseases (NIAID)	NULL	Terminated	2 Years	N/A	All	16	Phase 2	United States